02563.HK 股價走勢圖
BIOSTAR PHARM-B (02563.HK)
Beijing Biostar Pharmaceuticals Co., Ltd.
HK$3.84
-0.77%
$-0.03
休市： Apr 15, 16:00:00 HKT
返回
Beijing Biostar Pharmaceuticals Co., Ltd. (02563.HK)
關鍵數據
前收市價
$3.53
開盤價
$3.87
當日範圍
$3.84 - $3.89
52週區間
$2.4 - $10.58
交易量
21.8K
平均成交量
26.4K
股息收益率
--
每股盈餘 (TTM)
0.61
市值
$832.2M
什麼是 BIOSTAR PHARM-B？
Beijing Biostar Pharmaceuticals Co. Ltd. engages in the provision of treatment for tumor. The company is headquartered in Beijing, Beijing and currently employs 147 full-time employees. The company went IPO on 2024-10-31. The firm's products and pipeline mainly include Utidelone Injection, Utidelone Capsule, Utidelone Nanoformulation, Utidelone Antibody Drug Conjugate (ADC), BG22, BG18 and BG44. The firm's products are principally used for the treatment of relapsed or metastatic breast cancer, neoadjuvant treatment of human epidermal growth factor receptor 2 (HER2)-breast cancer neoadjuvant, advanced non-small cell lung cancer (NSCLC), solid tumors, breast cancer brain metastasis, lung cancer brain metastasis and other brain tumor indications. The firm mainly conducts its businesses in the domestic market.
